Relapse in a population based cohort of patients with polymyalgia rheumatica

Journal of Rheumatology

Volumn 32, Issue 1, 2005, Pages 65-73

  Kremers, Hilal Maradit ^a,b   Reinalda, Megan S ^a,c   Crowson, Cynthia S ^a,c   Zinsmeister, Alan R ^a,c   Hunder, Gene G ^a,d   Gabriel, Sherine E ^a,e  

^a MAYO CLINIC   (United States)

^b Division of Epidemiology   (Japan)

^c Division of Biostatistics

^d Division of Rheumatology   (Italy)

^e Division of Rheumatology   (United States)

Author keywords

Complications; Corticosteroid therapy; Polymyalgia rheumatica; Relapse

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HEALTH CARE; HIP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIGRATION; MORNING STIFFNESS; NECK PAIN; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; RHEUMATIC POLYMYALGIA; RHEUMATOLOGY; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 11844297342     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Doran M, Crowson C, O'Fallon W, Hunder G, Gabriel S. Trends in the incidence of polymyalgia rheumatica over a 30-year period in Olmsted County, Minnesota. J Rheumatol 2002;29:1694-7.
2. Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 1985;79:309-15.
3. Kyle V. Treatment of polymyalgia rheumatica/giant cell arteritis. Baillieres Clin Rheumatol 1991;5:485-91.
4. Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52:847-50.
5. Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;159:577-84.
6. Kurland L, Molgaard C. The patient record in epidemiology. Sci Am 1981;245:54-63.
7. Melton L. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
8. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
9. Therneau TM, Grambsch PM. Multiple events per subject. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000:189-229.
10. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: A retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;47:733-9.
11. Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 1999;26:1945-52.
12. Ostor AJK, Hazleman BL, Horton JC, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:2083-5.
13. Pountain G, Hazleman B. Erythrocyte sedimentation rate at presentation is a prognostic indicator for duration of treatment in polymyalgia rheumatica. Br J Rheumatol 1997;36:508-9.
14. Dolan AL, Moniz C, Dasgupta B, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997;40:2022-9.
15. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000;30:17-24.
16. Schreiber S, Buyse M. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin Rheumatol 1995;14:315-8.
17. Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis. A 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978;88:162-7.
18. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica. A 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
19. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999;26:1326-32.
20. Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 2001;30:260-7.
21. von Knorring J. Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients. Acta Med Scand 1979;205:429-35.
22. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981;40:1-5.
23. Bengtsson B, Malmvall B. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Acta Med Scand 1981;209:337-45.
24. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42:374-8.
25. Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996;39:304-7.
26. Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. Arch Intern Med 1997;157:317-20.
27. Proven A, Gabriel SE, O'Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999;26:1333-7.
28. Gabriel SE. Epidemiology of the rheumatic diseases. In: Harris ED, Ruddy S, Sledge CB, editors. Kelley's textbook of rheumatology. Vol 1. 6th ed. Philadelphia: WB Saunders Company; 2000:321-33.